Sell-Side Advisor
October 2017

Acquired by Mallinckrodt

Company Overview

  • Clinical-stage pharmaceutical and drug delivery device company developing and commercializing the proprietary use & delivery of XENEX™ (xenon) inhalation gas, to protect against brain cell death following acute neurologic injury


  • Xenon holds great promise due to its multiple mechanisms of action, extensive pre-clinical results1 and positive Phase II clinical trial results which demonstrated a reduction in brain tissue damage and directionally better survival outcomes (Results published in JAMA -Journal of the American Medical Association-, March 2016)

Value Provided by Frontcourt

  • Engaged to raise Series B Funding Round to continue latestage Phase III clinical development and explore all potential options
  • Conducted thorough due diligence including attending key industry events to identify company awareness and develop our strategy
  • Identified our target strategy of running a parallel process of capital raise efforts alongside exploring strategic alternatives
  • Created investor and M&A Overview presentations
  • Identified interested investors for a $40M Series B Round
  • Identified strategic buyers with interest in Drug Device and Neurology
  • Presented multiple options and ultimate recommendation to management and the Company
  • Facilitated successful US license of NeuroproteXeon by Mallinckrodt plc (NYSE:MNK)

We want to work with you

We can't wait to meet you. Hear your story. Connect.

Contact Us